Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No End In Sight: FDA Postpones Another In-Person Meeting Due To COVID-19

Executive Summary

The US agency had planned to hold an in-person meeting of its ophthalmic advisory committee in early June, indicating hope that things would be back to some form of normal by then. But due to the ongoing coronavirus pandemic, it has postponed that meeting until further notice.

You may also be interested in...



Webcasting The New Norm During COVID-19 As FDA Reschedules Opthalmic AdComm Panel

In a sign of the times, regulators are holding an advisory committee meeting for an ophthalmic device online because of the pandemic.

Sign Of Normalcy? US FDA Schedules Meeting But Pauses Non-COVID Guidance Development

As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.

Back To Normal? US FDA Schedules In-Person Meeting But Pauses Non-COVID Guidance Development

As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.

Related Content

Topics

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel